AML (Acute Myelogenous Leukemia)

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

30.0 / 100K

13 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Phase 2(13)

Drug	Company
conditioning regimen a	HWH International Inc. (HWH)
conditioning regimen b	HWH International Inc. (HWH)
conditioning regimen c	HWH International Inc. (HWH)
conditioning regimen d	HWH International Inc. (HWH)
conditioning regimen e	HWH International Inc. (HWH)
post-transplant abatacept	HWH International Inc. (HWH)
post-transplant mycophenolate mofetil	HWH International Inc. (HWH)
post-transplant tacrolimus	HWH International Inc. (HWH)
ptcy (25 mg/kg d3	HWH International Inc. (HWH)
ptcy (25 mg/kg d3	GH Research PLC (GHRS)
ptcy (50 mg/kg d3	HWH International Inc. (HWH)
ptcy (50 mg/kg d3	GH Research PLC (GHRS)
supportive care	HWH International Inc. (HWH)

BioSniper tracks 13 drugs in development for AML (Acute Myelogenous Leukemia) across 2 companies.

There are 2 clinical trials targeting AML (Acute Myelogenous Leukemia) tracked by BioSniper.

The estimated prevalence of AML (Acute Myelogenous Leukemia) is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.